VistaGen Therapeutics, Inc. (VTGN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1162547,
    "name": "VistaGen Therapeutics, Inc.",
    "stock_name": "VistaGen Therapeutics, Inc.",
    "full_name": "VistaGen Therapeutics, Inc.",
    "name_url": "stocks-analysis/vistagen-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "4.28",
    "chg": 0.68,
    "chgp": "18.89%",
    "dir": 1,
    "prev_price": "3.60",
    "mcapval": "107.24",
    "mcap": "",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US92840H4002",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.4 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vistagen-therapeutics-inc-1162547-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is VistaGen Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vistagen-therapeutics-inc-technically-bullish-or-bearish-3547290",
        "imagepath": "",
        "date": "2025-09-20 19:51:57",
        "description": "As of 26 August 2025, the technical trend for VistaGen Therapeutics, Inc. has changed from sideways to bullish. The weekly MACD is bullish, and the daily moving averages are also bullish, indicating positive momentum. However, the monthly MACD is only mildly bullish, and the Bollinger Bands show a bearish stance on the monthly timeframe. The KST is bullish weekly but bearish monthly, while the Dow Theory indicates a mildly bullish trend in both weekly and monthly perspectives. The OBV presents a mixed view, being mildly bearish weekly but bullish monthly.\n\nIn terms of performance, VistaGen has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of 3.05% versus 12.22% for the S&P 500, and a one-year return of 1.50% compared to 17.14% for the index. Overall, the current technical stance is bullish, but the strength is mixed, with some indicators showing caution...."
      },
      {
        "title": "Is VistaGen Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vistagen-therapeutics-inc-overvalued-or-undervalued-3543693",
        "imagepath": "",
        "date": "2025-09-20 18:26:03",
        "description": "As of 8 July 2024, the valuation grade for VistaGen Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.84 and an EV to EBITDA ratio of 0.37, which suggest that the market may not be accurately reflecting the underlying value of the company. Additionally, the ROCE stands at an impressive 773.04%, but this is overshadowed by a negative ROE of -58.31%, indicating challenges in generating returns for shareholders.\n\nIn comparison to its peers, VistaGen's valuation ratios are concerning, with Solid Biosciences, Inc. showing a worse EV to EBITDA of -0.8654 and Cognition Therapeutics, Inc. at -3.8036, both indicating significant struggles in profitability. The company's stock performance has also lagged behind the S&P 500, with a 5-ye..."
      }
    ],
    "total": 7,
    "sid": "1162547",
    "stock_news_url": "https://www.marketsmojo.com/news/vistagen-therapeutics-inc-1162547"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is VistaGen Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:51:57

As of 26 August 2025, the technical trend for VistaGen Therapeutics, Inc. has changed from sideways to bullish. The weekly MACD is bullish, and the daily moving averages are also bullish, indicating positive momentum. However, the monthly MACD is only mildly bullish, and the Bollinger Bands show a bearish stance on the monthly timeframe. The KST is bullish weekly but bearish monthly, while the Dow Theory indicates a mildly bullish trend in both weekly and monthly perspectives. The OBV presents a mixed view, being mildly bearish weekly but bullish monthly. In terms of performance, VistaGen has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of 3.05% versus 12.22% for the S&P 500, and a one-year return of 1.50% compared to 17.14% for the index. Overall, the current technical stance is bullish, but the strength is mixed, with some indicators showing caution....

Is VistaGen Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:26:03

As of 8 July 2024, the valuation grade for VistaGen Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.84 and an EV to EBITDA ratio of 0.37, which suggest that the market may not be accurately reflecting the underlying value of the company. Additionally, the ROCE stands at an impressive 773.04%, but this is overshadowed by a negative ROE of -58.31%, indicating challenges in generating returns for shareholders. In comparison to its peers, VistaGen's valuation ratios are concerning, with Solid Biosciences, Inc. showing a worse EV to EBITDA of -0.8654 and Cognition Therapeutics, Inc. at -3.8036, both indicating significant struggles in profitability. The company's stock performance has also lagged behind the S&P 500, with a 5-ye...

View All News